Quantitative Imaging and Proton Spectroscopy in Multiple Sclerosis

Quantitative MR Imaging and Proton Spectroscopy in MS

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01226654

Enrollment

Registered

2010-10-22

Start date

1991-08-31

Completion date

2016-04-30

Last updated

2017-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Keywords

Quantitative Imaging of Multiple Sclerosis

Brief summary

The primary purpose of this study is to detect changes in the brain that may be associated with multiple sclerosis. Results will be compared to age matched controls. Investigators will assess lesions by measuring T2 and T1 enhanced lesion volumes and magnetization transfer ratio histogram parameters (MTRHP) in patients with relapsing-remitting and secondary-progressive disease. This data will be correlated to total brain parenchymal volume as well as identifying the effect of MS lesions on the gray and white matter, volumetric disability, including Kurtzke Expanded Disability Status Scale (EDSS) and a specific battery of neuropsychological tests. Quantitative analysis of whole brain N-acetylaspartate (WBNAA), a reproducible measure of viable neuron number, using 1H MRS and compare the results to age-matched controls over duration of 5 years.

Interventions

DEVICEMagnetic Resonance Imaging

Magnetic Resonance Imaging EDSS

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

7 Years to 110 Years

Healthy volunteers

Yes

Inclusion criteria

1. Patients with known MS diagnosis 2. Age 7-110 years 3. Males or females

Exclusion criteria

1. Medically unstable 2. Artificial implants in the body 3. Pregnant Normal Controls

Design outcomes

Primary

Measure	Time frame	Description
Assess the MS lesions using Magnetization transfer ratio histogram parameters and compare it to total brain parenchymal volume	5 years	1\) Lesions will be assessed by measuring T2 and T1 enhanced lesion volumes and magnetization transfer ratio histogram parameters (MTRHP) in patients with relapsing-remitting and secondary-progressive disease. This data will be correlated to total brain parenchymal volume as well as identifying the effect of MS lesions on the gray and white matter, volumetric disability, including Kurtzke Expanded Disability Status Scale (EDSS) and a specific battery of neuropsychological tests

Secondary

Measure	Time frame	Description
Quantitative analysis of whole brain N-acetylaspartate (WBNAA)	5 years	Quantitative analysis of whole brain N-acetylaspartate (WBNAA), a reproducible measure of viable neuron number, using 1H MRS and compare the results to age-matched controls over duration of 5 years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026